Cells coexpressing both myeloid and endothelial markers are detectable in the spleen and bone marrow of patients with primary myelofibrosis

Exp Hematol. 2022 Dec:116:26-29. doi: 10.1016/j.exphem.2022.10.002. Epub 2022 Oct 14.

Abstract

Different bodies of evidence support the existence of a common origin of hematopoietic and endothelial lineages; moreover, recent studies have indicated the presence of a hemogenic endothelium and a common hemato-endothelial precursor both in the embryo and in the cord blood. Conversely, to our knowledge, there is no evidence of such bipotential cells in human postnatal tissues or blood. In this study, we investigated the presence and phenotype of "transitional" cells in different tissues of patients with primary myelofibrosis (PMF). Using confocal microscopy and flow cytometry, we identified a rare cell population in the bone marrow and spleen of patients with PMF, which coexpresses the endothelial marker CD144 (vascular endothelial (VE)-cadherin), the pan-hematopoietic marker CD45, the early myeloid marker CD33, and CD34, a common endothelial and hematopoietic antigen.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, CD34
  • Biomarkers
  • Bone Marrow
  • Bone Marrow Cells
  • Cell Differentiation
  • Hemangioblasts*
  • Humans
  • Primary Myelofibrosis*
  • Spleen

Substances

  • Antigens, CD34
  • Biomarkers